• Percent predicted FEV1 ≥ 40% by spirometry during screening

• Ability to demonstrate correct use of the smart DPI at screening, in the investigator's judgment

• On a stable treatment regimen for muco-obstructive diseases for ≥ 28 days prior to initiation of study treatment and willingness to remain on the stable treatment regimen through completion of study

• Stable disease for ≥ 28 days prior to screening and through to initiation of study treatment

⁃ Additional Inclusion Criteria for Participants in Part B

• Chronic sputum production of ≥1 teaspoon per day as reported in the sputum volume item

• Ability to produce a sputum sample that is suitable for central laboratory determination of mucus percent solids and sialic acid concentration exploratory biomarker research, and biomarker assay development

• Availability of a representative blood sample for exploratory biomarker research and biomarker assay development

⁃ Additional Inclusion Criteria for Participants With Non-cystic Fibrosis Bronchiectasis (NCFB) (Cohort 1, Cohort 2, and Cohort 3):

⁃ \- Diagnosis of bronchiectasis on the basis of prior chest computed tomography (CT), involving at least 2 lobes, with at least one lobe of involvement in the right lung as assessed by the investigator

⁃ Additional Inclusion Criteria for Participants With Chronic Obstructive Pulmonary Disease (COPD) (Cohort 1, Cohort 2, and Cohort 4):

• COPD defined as post-bronchodilator FEV1/FVC ratio of \<0.7

• Chronic bronchitis, with a definition including chronic cough and excessive sputum production for more than 3 months per year for at least 2 years prior to screening

• Former smoker with a minimum of 10 pack-year history (e.g., 20 cigarettes/day for 10 years) or non-smoker with at least one documented COPD risk factor